Díaz-Aristizabal U, Valdés-Vilches M, Fernández-Ferreras T R, Calero-Muñoz E, Bienzobas-Allué E, Aguilera-Ballester L, Carnicer-Cáceres J
Servicio de Rehabilitación y Medicina Física, Xarxa Sanitària i Social Santa Tecla, Tarragona, España.
Servicio de Rehabilitación y Medicina Física, Xarxa Sanitària i Social Santa Tecla, Tarragona, España.
Neurologia (Engl Ed). 2021 Mar 12. doi: 10.1016/j.nrl.2021.01.015.
This study aimed to assess the effects of botulinum toxin A (BTX-A) infiltration on face muscle function, synkinesis, and quality of life in patients with sequelae of peripheral facial palsy (PFP).
We present the results of a prospective study including a sample of 20 patients with sequelae of PFP (15 women, 5 men) who underwent BTX-A (Botox® or Xeomin®) infiltration. All patients had previously received personalised treatment with neuromuscular retraining. A clinical assessment was performed before BTX-A infiltration and 4weeks after treatment. The effect of BTX-A on face muscle function, quality of life, and synkinesis was evaluated using the Sunnybrook Facial Grading System (SFGS), the Facial Clinimetric Evaluation (FaCE) questionnaire, and the Synkinesis Assessment Questionnaire (SAQ), respectively.
Mean SFGS scores increased from 64.8 to 69.9 after BTX-A infiltration (P=.004). Increases were also observed in mean total FaCE scores (from 52.42 to 64.5; P<.001) and the mean score on the FaCE social function subscale (from 61.15 to 78.44; P<.001). Mean SAQ scores decreased from 46.22 to 37.55 after BTX-A infiltration (P=.001).
BTX-A infiltration increases face muscle function, improves quality of life, and reduces synkinesis in patients with sequelae of PFP.
本研究旨在评估A型肉毒毒素(BTX-A)局部注射对周围性面瘫后遗症(PFP)患者面部肌肉功能、联带运动及生活质量的影响。
我们呈现了一项前瞻性研究的结果,该研究纳入了20例PFP后遗症患者(15例女性,5例男性),他们接受了BTX-A(保妥适®或泽明®)局部注射。所有患者此前均接受过个性化的神经肌肉再训练治疗。在BTX-A局部注射前及治疗后4周进行了临床评估。分别使用桑尼布鲁克面部评分系统(SFGS)、面部临床计量评估(FaCE)问卷和联带运动评估问卷(SAQ)评估BTX-A对面部肌肉功能、生活质量和联带运动的影响。
BTX-A局部注射后,平均SFGS评分从64.8提高至69.9(P = 0.004)。平均总FaCE评分(从52.42提高至64.5;P < 0.001)以及FaCE社会功能子量表的平均评分(从61.15提高至78.44;P < 0.001)也有所增加。BTX-A局部注射后,平均SAQ评分从46.22降至37.55(P = 0.001)。
BTX-A局部注射可增强PFP后遗症患者的面部肌肉功能,改善生活质量,并减少联带运动。